Astellas Pharma ALPMY

OTC: ALPMY | ISIN: US04623U1025   3/07/2025
9,600 USD (-0,21%)
(-0,21%)   3/07/2025

7 mei 2025 · Notice of Nominees for Directors · Persbericht

1 mei 2025 · Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses · Persbericht

6 maart 2025 · Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing · Persbericht

11 september 2024 · Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 · Persbericht

5 september 2024 · Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies · Persbericht

4 september 2024 · Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society · Persbericht

28 augustus 2024 · European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer · Persbericht

27 augustus 2024 · Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy · Persbericht

20 augustus 2024 · China's National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer · Persbericht

26 juli 2024 · Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer · Persbericht

26 juli 2024 · Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer · Persbericht

22 juli 2024 · Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy · Persbericht

31 mei 2024 · U.s. Fda Acknowledges Astellas' Resubmission Of Biologics License Application For Zolbetuximab And Sets New Action Date · Persbericht

21 mei 2024 · Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies · Persbericht

13 mei 2024 · Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting · Persbericht

8 mei 2024 · Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor · Persbericht

2 mei 2024 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

24 april 2024 · Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting · Persbericht

22 april 2024 · Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs · Persbericht

28 maart 2024 · China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer · Persbericht

Mijn selecties